New York, June 15, 2026, 14:55 EDT
- RGNT traded up after Regentis pulled its F-1 IPO filing.
- The move took away near-term dilution risk, but funding questions remain.
- Next up on the calendar is European GelrinC surgeon training, now scheduled for Q3 2026.
Shares of Regentis Biomaterials Ltd. (RGNT) jumped on NYSE American Monday after the company said in an SEC filing it’s withdrawing its Form F-1 registration. The form allows foreign firms to list in the U.S., but Regentis said the offer won’t go forward and no shares were sold because the F-1 wasn’t effective. RGNT traded up about 677% at $11.65. The session saw the stock swing between $1.51 and $15.43 and over 161 million shares changed hands.
Regentis shares surged as traders put aside fears tied to a possible share sale. The company had filed May 1 to sell 3,333,334 ordinary shares at $3.00 each, plus an option for underwriters to buy another 500,000. Such a move often dilutes existing investors. That pressure eased, drawing buyers back in. RGNT was up more than 850% at one stage Monday, Stocktwits said, noting a spike in retail chatter in the previous day.
Bulls argue shelving the plan now eases share dilution risk as Regentis prepares for its first European launch. Regentis’s GelrinC, a hydrogel implant for knee cartilage, is the main product. The company said June 8 it will start surgeon training in Europe in the third quarter of 2026, as it gears up for launches in countries where GelrinC already has a CE Mark. “The initiation of surgeon training activities represents an important commercial milestone for Regentis in Europe,” CEO Dr. Ehud Geller said. FinanzNachrichten.de
Downside risk is back on the table. Regentis dropped the deal, which cuts risk of near-term dilution but shuts the door on new capital. The company posted a $13.6 million net loss for 2025, with a $55.8 million deficit and $7.4 million in cash at year end, according to its annual report. Its auditor called out the lack of revenue and ongoing losses, warning of “substantial doubt” Regentis can keep going as a going concern. That’s a signal Regentis will need to raise more cash to stay open. SEC
Regentis investors are focused on the upcoming European surgeon training for Q3 and a fresh SEC filing, which could shed light on how Regentis plans to fund its clinical, regulatory, and commercial work after scrapping the offering. Regentis says enrollment in the pivotal U.S. FDA trial for its GelrinC implant is now past the halfway mark. There’s also market interest in news on that study’s progress.
RGNT isn’t looking cheap at these prices, and the risk stands out. For stocks to climb, buyers need to believe there’s more value ahead, or the float must get tighter. Shares drop when optimism fades, more stock hits the market, cash drops, or the news lets people down. Monday’s bounce followed resolution of a financing overhang. This wasn’t driven by new sales, data from the FDA, or any trial results. Quick pops like this sometimes unwind just as fast, especially if RGNT faces cash trouble or delays in GelrinC commercialization set in.
